Diamyltryptamine

Diamyltryptamine
Clinical data
Other namesDAT; DAmT; N,N-Diamyltryptamine; Dipentyltryptamine; N,N-Dipentyltryptamine; DPeT
ATC code
  • None
Pharmacokinetic data
Onset of actionUnknown
Duration of actionUnknown
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]-N-pentylpentan-1-amine
Chemical and physical data
FormulaC20H32N2
Molar mass300.490 g·mol−1
3D model (JSmol)
  • CCCCCN(CCc1c[nH]c2c1cccc2)CCCCC
  • InChI=1S/C20H32N2/c1-3-5-9-14-22(15-10-6-4-2)16-13-18-17-21-20-12-8-7-11-19(18)20/h7-8,11-12,17,21H,3-6,9-10,13-16H2,1-2H3
  • Key:AXUJSLZQVYSFBL-UHFFFAOYSA-N

Diamyltryptamine (DAT), also known as N,N-dipentyltryptamine, is a chemical compound of the tryptamine family related to dimethyltryptamine (DMT). It is part of the homologous series of tryptamines that includes DMT, diethyltryptamine (DET), dipropyltryptamine (DPT), dibutyltryptamine (DBT), DAT itself, and dihexyltryptamine (DHT).

Use and effects

The compound was briefly mentioned by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), but he does not appear to have synthesized or tested it. Relatedly, the properties and effects of DAT are unknown. However, it is known that whereas DMT, DET, and DPT are fully effective psychedelics, DBT showed only weak psychedelic effects and DHT was inactive.

Chemistry

Analogues

N-Amyltryptamine

Chemical structure of N-amyltrytamine (NAT).

The N-monoamyl analogue of DAT, N-amyltryptamine (NAT), has also been described. According to Stephen Szara and Alexander Shulgin, this compound was inactive at a dose of up to 100 mg orally.

History

DAT was first described in the scientific literature by Stephen Szara and colleagues in 1962, who studied its metabolism (specifically 6-hydroxylation) in vitro.

See also